Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:clinical_focus |
oncology
prostate cancer |
| gptkbp:delistedDate |
2023
|
| gptkbp:focus |
radiopharmaceuticals
|
| gptkbp:founded |
2019
|
| gptkbp:founder |
gptkb:Dr._Joe_McCann
|
| gptkbp:headquarters_location |
gptkb:Indianapolis,_Indiana,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Point Biopharma
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:numberOfEmployees |
approximately 100 (as of 2023)
|
| gptkbp:parentOrganization |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:pipeline |
gptkb:PNT2001
gptkb:PNT2002 gptkb:PNT2003 gptkb:PNT2004 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
targeted radioligand therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:PNT
|
| gptkbp:website |
https://www.pointbiopharma.com/
|
| gptkbp:bfsParent |
gptkb:Eli_Lilly
|
| gptkbp:bfsLayer |
6
|